are unduly sanguine about their ability accurately to diagnose pulmonary embolism using the methods available in 1960. Two larger studies, using angiography and post-mortem data to establish the pathology, have concluded that the accuracy of clinical diagnosis is closer to 40% (Hildner & Ormond 1967 ,Modan et al. 1972 .
I doubt whether most physicians would consider haemoptysis and pleuritic chest pain as indicating pulmonary infarction. On one medical ward in the last month I have seen three cases of undoubted pneumococcal pneumonia presenting with pleuritic chest pain and haemoptysis.
It has become increasingly clear over recent years that clinical impressions are a very poor judge of therapeutic efficacy in self-limiting disorders, particularly where expectation of benefit is high.
It is clear that clinical expectations of oral anticoagulants, for example, were very high from the outset. In the words of the discoverer of bishydroxycoumarin, Paul Link, after rudimentary studies in animal toxicology, this drug was 'grabbed from his hands by the clinicians'. The curious situation has arisen where, rather than the proponents of anticoagulant therapy having to prove benefits from this treatment, sceptics, like myself, are placed in the impossible situation of having to prove that they donot work.
The issue is clouded somewhat by a semantic confusion. Anticoagulants are undoubtedly effective in preventing clot formation. As long as clinicians talk loosely about 'clots in the lungs', many will feel subconsciously that any formal demonstration of therapeutic benefit is superfluous. However, the structure and composition of a clot in a test tube is very different from that of a thrombus in a vein. The evidence for an anti thrombotic effect of anticoagulants in humans is elusive.
An interesting analogy may be found in the anticoagulant treatment of myocardial infarction (MI). In the days when it was commonly assumed that MI was caused by in situ thrombosis, anticoagulants were in widespread use for this disease and the results of several large trials were even more spectacular than the results reported by Barritt & Jordan (1960) for pulmonary embolism. Gifford & Feinstein (1969) have pointed out that the most impressive results were obtained in the trials with the poorest experimental design. Now that the theory of pathophysiology has changed somewhat, anticoagulants have falIen out of favour in this application.
It is important to emphasize that heparin and warfarin are very dangerous drugs, The mortality of heparin in one prospective trial has been 2%, the morbidity close to 40% (Salzmann et al. 1975) . It is ethicalIy unacceptable to use these drugs in the vague hope that they may be doing some good, or simply because no better treatment is available. Human campylobacter infections are common in Britain; some 8000, the majority of them symptomatic, have been reported to the Communicable Diseases Surveillance Centre so far this year. Because of the numerical importance of the infection and its novelty, much work has been done in unravelling the basic epidemiological features ofthe disease in man.
The thing that became apparent early on was the sporadic nature of the infection. With the exception of a number of .common food or environmental source outbreaks, almost all cases can be classified as 'isolated', and investigation of the contacts only rarely turns up asymptomatic infections. Investigation of the source cases of Journal of the Royal Society of Medicine Volume 74 December 1981 943 campylobacteriosis are not often fruitful, but when they are the evidence almost invariably points to animals as the primary source, either by direct transmission (consumption of animal products, contact with faeces or animals) or indirectlythrough the environmen1.
Transmission from person to person certainly can occur, but the only circumstances under which it occurs readily appear to be from children with diarrhoea to their parents or to other children. Nursery school outbreaks have been reported. Infected adults, with or without symptoms, do not seem to act as a reservoir of any importance for either direct or indirect transmission.
In summary, Firstly, Dr Hill, in choosing nitrous oxide as an anaesthetic agent that stimulates 'the endogenous opioid operated pain modification system by many different inputs', has chosen a poor example. There is some positive evidencethat N20 acts both in vitro (Ahmed & Byrne 1980) and in vivo (Gillman et al. 1980 , Gillman & Lichtigfeld 19810, b. Berkowitz et 01. 1917 as an opiate agonist.
Secondly, he fails to mention a very interesting anomaly that has direct bearing on an understanding of the opioid system and its involvement in pain modulation. This is the fact that naloxone has been shown on a number of occasions and by different workers to cause analgesia (Gillman et al. 1980 , Gillman & Lichtigfeld 1981a , Lasagna 1965 , Woolf 1980 , Levine et al. 1979 ). Since naloxone has been shown not to have agonist properties (Jasinski et 01. 1967) at low doses, this provides the possible exciting idea of two balanced opposing systems, one opioid, and the other anti-opioid that modulates pain perception. This hypothesis is further strengthened by the biphasic effect observed, viz., low concentrations of naloxone causing analgesia (Gillman et al. 1980 , Gillman & Lichtigfeld 19810, Levine et 01. 1979 and high concentrations hyperalgesia (Levine et 01. 1979 , Yang et al. 1980 . This hypothesis has been dealt withelsewherein detail (Gillman et al. 1981) . 
